FOLD · AMICUS THERAPEUTICS, INC.

Track FOLD — free

Market Cap

$4.55B

314.00M

No Price Data

No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-K

filed Feb 20, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Limited Momentum Limited Sentiment Bearish Fundamentals Excellent Quant / Vol Limited

Market backdrop VIX 15.1 · calm Equity put/call 0.51

Technical

price trend

Limited

Not enough data for a confident read.

Momentum

relative strength

Limited

Not enough data for a confident read.

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50/200-day averages unavailable

Institutional flow Distributing

-99% holders QoQ

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

6.98% of float · ▲ +3.9% MoM · 7.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

2 holders — near 3-yr low, contrarian setup

Fundamentals

Excellent

Revenue growth +20%

Y/Y

Gross margin 89%

contracting

EPS growth +50%

Y/Y

Free cash flow $29.8M

Balance sheet $178.7M

net debt

Quant / Vol

risk profile

Limited

Not enough data for a confident read.

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Sep 30, 2025

Combined sales · 2028 $1B

Prior guidance period ended · from the 8-K filed Nov 4, 2025

Galafold Revenue Growth · FY 2025 10% – 15%

Pombiliti + Opfolda Revenue Growth · FY 2025 50% – 65%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Non-GAAP net income non-GAAP	$31.6M	Q4 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FOLD AMICUS THERAPEUTICS, INC. this stock	$4.55B	—	+20.0%	—	7.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$138.91B	+20.9%	+46.2%	31.9	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$85.87B	+8.1%	+20.8%	20.7	3.3%
ARGX Argenx SE	$64.66B	+23.6%	—	—	2.1%
CSLLY Csl Ltd	$57.97B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 0.0%
Net QoQ: -333.6M sh
Top holder: IFP Advisors, Inc

Held Float

View

Held by Funds

Fund positions

111

View

Short & Settlement

Short Interest Rising

Shares short

21.9M

Days to cover: 7.5d
Change: +824.6K sh

View

Short Volume

Short vol %

73%

As of: Apr 24, 2026

Short Total

View

Fails to Deliver

FTD shares

3.5K

Value: $50.6K
As of: Apr 28, 2026

View

Smart Money

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Apr 10, 2023

View

Financials

Revenue (FY)

$634.2M

Net income (FY): $-27.1M
EPS diluted: $-0.09

View

Filings

SEC Filings

Latest

8-K

Filed: Apr 27, 2026
This year: 6

View

Proposed Sales

Value

$323.3K

Shares: 22.5K
Filed: Mar 2, 2026

View

Exempt Offerings

Offering

$30.0M

Filed: Oct 16, 2023

View

Earnings & Events

Earnings Calls

Last call

May 4, 2026

View

Key facts CIK 1178879 CUSIP 03152W109 13F (30d) 12 filings 5 filers Visit website Investor relations